A new study published in Nature Metabolism (2026) reveals that inducible nitric oxide synthase (iNOS) possesses a previously unrecognized second function: it physically sequesters IRG1 (also known as ACOD1) within mitochondria, preventing the enzyme from generating the anti-inflammatory metabolite itaconate. This occurs independently of iNOS's canonical nitric oxide (NO) production and depends on the protein's BH4-stabilized conformation. While the MedicalXpress coverage accurately reports the core binding discovery and its potential for Crohn's disease, rheumatoid arthritis, and atherosclerotic heart disease, it underplays the finding's placement within the broader immunometabolism revolution and overstates immediate clinical translation.

This is not a large-scale RCT but a preclinical mechanistic study relying on co-immunoprecipitation, mass spectrometry, surface plasmon resonance, computational modeling, and cellular assays in both murine and human macrophages. Sample sizes for functional experiments appear modest (typical n=3-6 biological replicates), with no declared conflicts of interest from the University of Surrey and Oxford teams. The work builds rigorously on prior observations yet fills a critical gap: the field long assumed iNOS primarily acts via NO and downstream cGMP signaling. This paper demonstrates that iNOS mutants lacking catalytic activity still suppress itaconate production by >15-fold upon LPS stimulation, while BH4-binding mutants do not.

What the original coverage missed is the deeper connection to metabolic reprogramming patterns identified in the last decade. A landmark 2018 Nature paper by Mills et al. (DOI: 10.1038/s41586-018-0015-4) established that IRG1-derived itaconate alkylates KEAP1 to activate Nrf2, dampening IL-1β and providing a brake on pro-inflammatory macrophages. Subsequent 2021 work in Nature Metabolism by the O'Neill laboratory further linked itaconate to succinate dehydrogenase inhibition, altering mitochondrial respiration. The current study synthesizes these threads by showing iNOS physically hijacks IRG1, redirecting its partnerships toward glycolytic regulators rather than anti-inflammatory metabolites. This sequestration effect was overlooked in earlier iNOS knockout studies that attributed all phenotypes solely to absent NO.

The implications extend beyond inflammation control. In rheumatoid arthritis, synovial macrophages exhibit sustained iNOS expression; in Crohn's, intestinal lamina propria cells show dysregulated itaconate levels (per a 2022 Gastroenterology observational cohort of 87 patients). In cardiovascular disease, plaque macrophages drive IL-6 and TNF-α partly through mitochondrial ROS. By revealing iNOS as a structural modulator rather than mere enzyme, the Surrey-Oxford team identifies a druggable protein-protein interface that could spare homeostatic NO signaling from endothelial NOS (eNOS), which notably does not bind IRG1.

Past attempts to inhibit iNOS enzymatically failed in phase II trials for sepsis and arthritis due to off-target hypotension and impaired host defense. Targeting the iNOS-IRG1 interface offers precision: small molecules or peptides could selectively free IRG1, allowing endogenous itaconate to rise only in inflamed tissue. This aligns with the emerging 'moonlighting protein' paradigm seen in GAPDH and PKM2, where metabolic enzymes acquire immune regulatory roles based on localization and conformation.

Limitations remain. The study primarily used immortalized cell lines and murine models; human tissue validation is preliminary. Whether this interaction dominates in polarized T cells or fibroblasts central to fibrosis in heart disease and Crohn's requires further observational and eventual interventional human studies. Nonetheless, by shifting focus from 'what iNOS produces' to 'what iNOS binds,' this discovery supplies a mechanistic blueprint that could reduce the adverse effects plaguing current broad-spectrum anti-inflammatories affecting over 50 million patients worldwide with these conditions.